Respiratory rare disease trials come with challenges ranging from the demand placed on sites and patients to managing multiple vendors and ensuring diversity. Achieving success in respiratory rare disease trials requires a flexible approach, a strong emphasis on site selection and key opinion leaders (KOLs) with a deep regulatory understanding.
Join this webinar to hear from subject matter experts (SMEs) on their insights into developing and evaluating rare disease trials in multiple respiratory indications, and learn strategies to overcome obstacles that arise in the clinical development, testing and regulatory approval of treatments for rare diseases.
Francis Jones, Senior Director Project Management – Respiratory, PPD
Francis Jones is the Senior Director in the PPD Infectious, Respiratory and Critical Care Diseases group with more than 23 years of drug development experience working for Pharma and CRO. His current role focuses on respiratory clinical trial strategy development — early engagement, proposal writing, reviewing trial protocols and helping clients design optimized clinical trials. Francis has extensive experience leading global clinical trials across a range of respiratory indications and received his Pharmacology PhD from Cardiff Medical School in the UK.
Christian Lloyd, Associate Medical Director, PPD
Christian Lloyd is a board-certified Pulmonary/Critical/Sleep specialist since 2002. Christian Joined PPD/ Thermo Fisher Scientific in 2021. Before joining PPD, Christian served as the Director of Medical Intensive Care Services for a large referral healthcare system. Christian completed a Master of Health Care Administration at the University of North Carolina in 2017 and is passionate about critical care delivery, therapeutic product development and approval as well as improving value-based healthcare delivery.
Terri Myers, Global Head of Biotech Operations, PPD
Terri Myers serves as vice president and global head of PPD Biotech operations where she oversees operational and partnership delivery models tailored to meet the needs of our rapidly growing biotech clients. Terri has held clinical research roles the past 23 years, including a proven 17-year history in operations and strategic solution development working in various capacities in the complex space of rare disease development. Myers completed her Master of Business Administration at the University of North Carolina, Wilmington, and holds a bachelor’s degree in economics with a minor in international studies from Wake Forest University.
Who Should Attend?
This webinar will appeal to professionals in the following roles:
- Chief Medical Officer
- Clinical Development
- Chief Scientific Officer
- Clinical Operations
What You Will Learn
Attendees will gain insights about:
- Protocol and regional considerations
- Digital/decentralized solutions
- Site and patient centricity
- Ensuring diversity
- Vendor management
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, its capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, PPD clinical research serves pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, the business applies cutting-edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.